Abeona Therapeutics Inc. (ABEO) NASDAQ
5.72
+0.0401(+0.71%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
5.72
+0.0401(+0.71%)
Currency In USD
| Previous Close | 5.68 |
| Open | 5.81 |
| Day High | 5.93 |
| Day Low | 5.53 |
| 52-Week High | 7.54 |
| 52-Week Low | 4 |
| Volume | 2.13M |
| Average Volume | 1.2M |
| Market Cap | 326.33M |
| PE | 5.66 |
| EPS | 1.01 |
| Moving Average 50 Days | 5.08 |
| Moving Average 200 Days | 5.39 |
| Change | 0.04 |
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch
GlobeNewswire Inc.
Mar 09, 2026 11:30 AM GMT
CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company’s launch of FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gen
Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference
GlobeNewswire Inc.
Mar 03, 2026 12:30 PM GMT
CLEVELAND, March 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and c
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
GlobeNewswire Inc.
Dec 15, 2025 12:30 PM GMT
CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the C